Management of chronic hepatitis C treatment failures: role of consensus interferon

References

• BellBPManosMMZamanAThe epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillanceAm J Gastroenterol2008103112727273618684170
   PubMed Web of Science ®Google Scholar
• SeeffLBNatural history of chronic hepatitis CHepatology2002365 Suppl 1S35S4612407575
   PubMed Web of Science ®Google Scholar
• PoynardTMcHutchisonJMannsMImpact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis CGastroenterology200212251303131311984517
   PubMed Web of Science ®Google Scholar
• CraxiACammaCPrevention of hepatocellular carcinomaClin Liver Dis200592329346viii15831277
   PubMedGoogle Scholar
• MaylinSMartinot-PeignouxMMoucariREradication of hepatitis C virus in patients successfully treated for chronic hepatitis CGastroenterology2008135382182918593587
   PubMed Web of Science ®Google Scholar
• MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet2001358928695896511583749
   PubMed Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med20023471397598212324553
   PubMed Web of Science ®Google Scholar
• HadziyannisSJSetteHJrMorganTRPeginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin doseAnn Intern Med2004140534635514996676
   PubMed Web of Science ®Google Scholar
• MuirAJBornsteinJDKillenbergPGPeginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whitesN Engl J Med2004350222265227115163776
   PubMed Web of Science ®Google Scholar
• HoofnagleJHMullenKDJonesDBTreatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary reportN Engl J Med198631525157515783097544
   PubMed Web of Science ®Google Scholar
• PoynardTMarcellinPLeeSSRandomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)Lancet19983529138142614329807989
   PubMed Web of Science ®Google Scholar
• McHutchisonJGGordonSCSchiffERInterferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy GroupN Engl J Med199833921148514929819446
   PubMed Web of Science ®Google Scholar
• StraderDBWrightTThomasDLSeeffLBDiagnosis, management, and treatment of hepatitis CHepatology20043941147117115057920
   PubMed Web of Science ®Google Scholar
• DavisGLWongJBMcHutchisonJGMannsMPHarveyJAlbrechtJEarly virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis CHepatology200338364565212939591
   PubMed Web of Science ®Google Scholar
• ShiffmanMLDi BisceglieAMLindsayKLPeginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatmentGastroenterology200412641015102315057741
   PubMed Web of Science ®Google Scholar
• JacobsonIMGonzalezSAAhmedFA randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis CAm J Gastroenterol2005100112453246216279900
   PubMed Web of Science ®Google Scholar
• MathewAPeifferLPRhoadesKMcGarrityTSustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatmentDig Dis Sci200651111956196117004124
   PubMed Web of Science ®Google Scholar
• ShermanMYoshidaEMDeschenesMPeginterferon alfa-2a (40 KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapyGut200655111631163816709661
   PubMed Web of Science ®Google Scholar
• KrawittELAshikagaTGordonSRFerrentinoNRayMALidofskySDPeginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis CJ Hepatol200543224324916082735
   PubMed Web of Science ®Google Scholar
• BassoMTorreFGrassoAPegylated interferon and ribavirin in re-treatment of responder-relapser HCV patientsDig Liver Dis2007391475117079197
   PubMedGoogle Scholar
• MoucariRRipaultMPOulesVHigh predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapyJ Hepatol200746459660417218037
   PubMed Web of Science ®Google Scholar
• TalianiGGemignaniGFerrariCPegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patientsGastroenterology200613041098110616618404
   PubMed Web of Science ®Google Scholar
• GaleMJrFoyEMEvasion of intracellular host defence by hepatitis C virusNature2005436705393994516107833
   PubMed Web of Science ®Google Scholar
• van PeschVLanayaHRenauldJCMichielsTCharacterization of the murine alpha interferon gene familyJ Virol200478158219822815254193
   PubMed Web of Science ®Google Scholar
• BlattLMDavisJMKleinSBTaylorMWThe biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferonJ Interferon Cytokine Res19961674894998836913
   PubMed Web of Science ®Google Scholar
• Infergen® (Interferon alfacon-1) [package insert] Revised July 27, 2006Valeant PharmaceuticalsCosta Mesa, CA, USA
   Google Scholar
• FattovichGZagniIMinolaEA randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis CJ Hepatol200339584384914568269
   PubMed Web of Science ®Google Scholar
• RustgiVKBonkovskyHLAroraSZeuzemSPMannsMBlattLMDaily versus three-times-weekly IFN Alfacon-1 in previously untreated HCV patients results in a significantly greater rate of SVR: Final results of an international, phase 4 study [abstract S1541]Gastroenterology20051284 Suppl 2A-716
   Web of Science ®Google Scholar
• TongMJReddyKRLeeWMTreatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study GroupHepatology19972637477549303508
   PubMed Web of Science ®Google Scholar
• JensenDMKrawittELKeeffeEBBiochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study GroupAm J Gastroenterol199994123583358810606323
   PubMed Web of Science ®Google Scholar
• SjogrenMHSjogrenRHoltzmullerKInterferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis CDig Dis Sci200550472773215844709
   PubMed Web of Science ®Google Scholar
• SjogrenMHSjogrenRJrLyonsMFAntiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirinDig Dis Sci20075261540154717406822
   PubMed Web of Science ®Google Scholar
• HeathcoteEJKeeffeEBLeeSSRe-treatment of chronic hepatitis C with consensus interferonHepatology1998274113611439537455
   PubMed Web of Science ®Google Scholar
• HeathcoteEJJamesSMullenKDHauserSCRosenblateHAlbertDGJrChronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study GroupHepatology199930256256610421669
   PubMed Web of Science ®Google Scholar
• MiglioresiLBacosiMRussoFConsensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infectionHepatol Res200327425325914662112
   PubMed Web of Science ®Google Scholar
• BarbaroGBarbariniGConsensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot studyEur J Gastroenterol Hepatol200214547748311984144
   PubMed Web of Science ®Google Scholar
• MoskovitzDNManoharanPHeathcoteEJHigh dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis CCan J Gastroenterol200317847948212945008
   PubMed Web of Science ®Google Scholar
• KaiserSHassHGGregorMSuccessful retreatment of interferon/ribavirin nonresponders with daily dosing of consensus interferon [abstract 570]J Hepatol200542 Suppl 2207208
   Google Scholar
• BocherWOSchuchmannMLinkRConsensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapyLiver Int200626331932516584394
   PubMed Web of Science ®Google Scholar
• CornbergMHademJHerrmannETreatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot studyJ Hepatol200644229130116360972
   PubMed Web of Science ®Google Scholar
• LaydenTJLaydenJEReddyKRLevy-DrummerRSPoulakosJNeumannAUInduction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis CJ Viral Hepat20029533433912225327
   PubMed Web of Science ®Google Scholar
• AlaimoGDi MarcoVFerraroDDifferent doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trialWorld J Gastroenterol200612426861686417106937
   PubMed Web of Science ®Google Scholar
• da SilvaLCBassitLOno-NitaSKHigh rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot studyJ Gastroenterol200237973273612375147
   PubMed Web of Science ®Google Scholar
• GhalibRHLevineCDFriedmanDARashdanSSchwartzAGWeinsteinJConsensus interferon plus ribavirin therapy in patients who are nonresponders or relapsers to prior PEG IFN plus ribavirin [abstract M1874]Gastroenterology20071324 Suppl 2A-794
   Web of Science ®Google Scholar
• KaiserSLutzeBSauterBRetreatment of HCV genotype 1 relapse patients to peginteferon/ribavirin therapy with an extended treatment regimen of 72 weeks with consensus interferon/ribavirin versus peginterferon alpha/ribavirin [abstract 1310]Hepatology2007464 Suppl 1819A
   Web of Science ®Google Scholar
• BaconBRegevAGhalibRHThe DIRECT trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): Treatment of non-responders to previous pegylated interferon plus ribavirin: Sustained virologic response data [abstract 168]Hepatology2007464 Suppl 1311A312A
   Web of Science ®Google Scholar
• LeevyCBConsensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirinDig Dis Sci20085371961196618219576
   PubMed Web of Science ®Google Scholar
• BergTvon WagnerMNasserSExtended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirinGastroenterology200613041086109716618403
   PubMed Web of Science ®Google Scholar